Advanced

Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS

Andersson, Karl-Erik LU ; Uckert, Stefan; Stief, Christian and Hedlund, Petter LU (2007) In Neurourology and Urodynamics 26(6). p.928-933
Abstract
Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT... (More)
Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prostatic hypertrophy(BPH), (cGMP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate, sildenafil, tadalafil, vinpocetine
in
Neurourology and Urodynamics
volume
26
issue
6
pages
928 - 933
publisher
John Wiley & Sons
external identifiers
  • wos:000250196200008
  • scopus:35148853274
ISSN
0733-2467
DOI
10.1002/nau.20485
language
English
LU publication?
yes
id
45edb0d2-7968-49ab-9a28-600cc0a5d47f (old id 655117)
date added to LUP
2007-12-05 13:38:16
date last changed
2017-10-01 03:37:40
@article{45edb0d2-7968-49ab-9a28-600cc0a5d47f,
  abstract     = {Lower urinary tract (LUT) smooth muscle can be relaxed by drugs that increase intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both of these substances are degraded by phosphodiesterases (PDEs), which play a central role in the regulation of smooth muscle tone. The distribution and functional significance of PDE enzymes vary in different tissues of the LUT. Targeting specific PDE isoenzymes should thus allow organ selectivity. PDE 4 and 5 appear to predominate in the prostate, PDE 1 and 4 are thought to influence detrusor smooth muscle function, and PDE 5 may be functionally important in the urethra and vasculature. Studies on the use of PDE inhibitors to treat various LUT symptoms (LUTS), have yielded favorable results. Thus, positive effects of the PDE 5 inhibitors sildenafil and tadalafil on symptoms and quality of life in men with LUTS, erectile dysfunction, and BPH have also been demonstrated. These effects may be due to effects on cGMP signaling and/or modification of afferent input from bladder, urethral, and prostate tissue. This review gives an update on the distribution of PDEs in structures relevant for LUT function, and discusses how inhibition of these enzymes can contribute to beneficial effects on LUTS. Information for the review was obtained from searches of the PubMed database, and from the authors' files.},
  author       = {Andersson, Karl-Erik and Uckert, Stefan and Stief, Christian and Hedlund, Petter},
  issn         = {0733-2467},
  keyword      = {prostatic hypertrophy(BPH),(cGMP),cyclic adenosine monophosphate (cAMP),cyclic guanosine monophosphate,sildenafil,tadalafil,vinpocetine},
  language     = {eng},
  number       = {6},
  pages        = {928--933},
  publisher    = {John Wiley & Sons},
  series       = {Neurourology and Urodynamics},
  title        = {Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS},
  url          = {http://dx.doi.org/10.1002/nau.20485},
  volume       = {26},
  year         = {2007},
}